Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride
NCT02263547 · Derrick Scott Robertson · PHASE1 · terminated · last registry update 2020-04-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PK time points were not being met as expected. Determination that risks outweighed benefit.” | – | Registry record, Derrick Scott Robertson |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHODH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-03-09Phase 3 first posted: Novartis Pharmaceuticals, Ofatumumab + First line DMT (NCT04788615)
- 2020-11-30Results posted on the registry: Genzyme, a Sanofi Company, Teriflunomide + Placebo (NCT02201108)
- 2020-10-19Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab subcutaneous injection + Teriflunomide-matching placebo capsules (NCT02792231)
- 2020-10-19Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab subcutaneous injection + Teriflunomide-matching placebo capsules (NCT02792218)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586010)
- 2020-10-14Phase 3 first posted: Hoffmann-La Roche, Fenebrutinib + Teriflunomide (NCT04586023)
- 2020-08-12Results posted on the registry: Northwestern University, Standard treatment with a conventional drug (NCT00273364)
- 2020-06-19Phase 3 first posted: PTC Therapeutics, PTC299 + Placebo (NCT04439071)
- 2020-06-01Phase 3 first posted: Sanofi, Tolebrutinib + Teriflunomide (NCT04410978)
- 2020-06-01Phase 3 first posted: Sanofi, Tolebrutinib + Teriflunomide HMR1726 (NCT04410991)
- 2020-05-07Phase 3 first posted: Immunic AG, IMU-838 (NCT04379271)
- 2020-04-08Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338022)
- 2020-04-08Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Teriflunomide + Evobrutinib (NCT04338061)
- 2019-05-10Also stopped (terminated): PTC Therapeutics, PTC299 + Docetaxel (NCT00704821)
- 2019-04-12Also stopped (terminated): PTC Therapeutics, PTC299 (NCT00911248)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision